Patients with LEI > 0 (N = 479) | ||||||
---|---|---|---|---|---|---|
Locationa | Severityb | |||||
Lateral epicondyle humerus N = 331 | Medial femoral condyle N = 285 | Achilles tendon insertion N = 260 | 1 site N = 105 | 2 sites N = 127 | 3–6 sites N = 246 | |
Tofacitinib 5 mg BID | N = 102 | N = 94 | N = 87 | N = 37 | N = 47 | N = 73 |
Tofacitinib 10 mg BID | N = 119 | N = 100 | N = 92 | N = 31 | N = 37 | N = 95 |
Placebo | N = 110 | N = 91 | N = 81 | N = 37 | N = 43 | N = 78 |
Female, n (%) | 58 (56.9) | 49 (52.1) | 47 (54.0) | 19 (51.4) | 26 (55.3) | 39 (53.4) |
80 (67.2) | 66 (66.0) | 55 (59.8) | 14 (45.2) | 20 (54.1) | 66 (69.5) | |
68 (61.8) | 60 (65.9) | 50 (61.7) | 15 (40.5) | 26 (60.5) | 53 (67.9) | |
Age, years, mean (SD) | 50.8 (11.8) | 49.2 (11.6) | 48.7 (12.2) | 50.0 (11.6) | 49.4 (11.5) | 49.7 (12.1) |
50.6 (11.6) | 50.2 (11.5) | 50.5 (11.6) | 48.2 (13.5) | 48.4 (11.5) | 51.4 (11.3) | |
49.2 (13.0) | 49.3 (12.3) | 49.6 (12.4) | 48.1 (13.2) | 50.0 (13.0) | 49.6 (12.7) | |
Race, White, n (%) | 96 (94.1) | 89 (94.7) | 83 (95.4) | 35 (94.6) | 46 (97.9) | 69 (94.5) |
112 (94.1) | 94 (94.0) | 88 (95.7) | 28 (90.3) | 34 (91.9) | 92 (96.8) | |
104 (94.5) | 85 (93.4) | 77 (95.1) | 34 (91.9) | 41 (95.3) | 73 (93.6) | |
BMI, kg/m2, mean (SD) | 30.2 (6.4) | 31.0 (6.9) | 30.8 (6.3) | 29.1 (7.3) | 30.7 (7.1) | 30.4 (6.0) |
30.7 (6.3) | 31.0 (6.5) | 30.6 (6.8) | 29.3 (5.6) | 29.3 (6.9) | 31.1 (6.5) | |
29.7 (5.8) | 29.5 (5.8) | 30.4 (6.1) | 29.9 (4.7) | 29.3 (5.9) | 30.0 (6.2) | |
PsA duration, years, mean (SD) | 7.6 (6.6) | 9.6 (8.5) | 8.7 (7.7) | 10.4 (9.4) | 7.5 (7.1) | 8.5 (7.2) |
6.9 (5.9) | 7.5 (5.8) | 7.6 (6.3) | 7.1 (5.2) | 6.8 (6.9) | 7.5 (5.9) | |
7.5 (6.0) | 8.5 (7.8) | 8.0 (6.8) | 10.0 (8.9) | 9.5 (7.1) | 6.8 (5.9) | |
CRP, mg/L, mean (SD) | 9.8 (16.1) | 11.3 (18.0) | 13.8 (22.5) | 17.4 (26.9) | 17.1 (29.4) | 8.3 (8.3) |
11.0 (20.9) | 16.3 (29.9) | 13.6 (27.8) | 14.7 (21.1) | 8.9 (15.1) | 14.5 (28.7) | |
10.6 (21.0) | 11.2 (18.9) | 10.5 (17.7) | 17.7 (33.4) | 9.7 (11.3) | 9.4 (16.5) | |
LEI, mean (SD) | 3.3 (1.6) | 3.4 (1.6) | 3.3 (1.7) | 1.0 (0.0) | 2.0 (0.0) | 4.2 (1.1) |
3.7 (1.7) | 4.0 (1.6) | 3.9 (1.8) | 1.0 (0.0) | 2.0 (0.0) | 4.4 (1.1) | |
3.3 (1.6) | 3.5 (1.5) | 3.4 (1.7) | 1.0 (0.0) | 2.0 (0.0) | 4.1 (1.1) | |
SPARCC, mean (SD) [N1]c | 7.2 (3.8) [95] | 7.2 (3.9) [88] | 6.9 (4.2) [82] | 2.7 (1.8) [33] | 5.0 (2.4) [44] | 8.4 (3.6) [70] |
7.6 (4.3) [116] | 8.3 (4.1) [95] | 8.1 (4.4) [89] | 2.3 (1.7) [30] | 5.2 (2.3) [35] | 8.9 (3.7) [92] | |
6.6 (3.8) [105] | 7.0 (3.6) [85] | 6.7 (3.7) [76] | 2.8 (1.8) [36] | 4.5 (2.7) [39] | 8.0 (3.4) [74] | |
Dactylitis presence, DSS > 0, n (%) | 56 (54.9) | 56 (59.6) | 53 (60.9) | 19 (51.4) | 25 (53.2) | 46 (63.0) |
65 (54.6) | 53 (53.0) | 52 (56.5) | 15 (48.4) | 22 (59.5) | 51 (53.7) | |
59 (53.6) | 50 (54.9) | 48 (59.3) | 17 (45.9) | 21 (48.8) | 46 (59.0) | |
TJC68, mean (SD) [N1]d | 26.2 (14.4) [49] | 24.8 (15.1) [41] | 21.8 (14.3) [34] | 18.2 (11.6) [18] | 21.2 (10.5) [28] | 28.3 (16.0) [28] |
25.8 (13.4) [50] | 24.9 (11.8) [36] | 27.4 (14.5) [33] | 17.4 (9.5) [13] | 22.6 (16.5) [16] | 28.3 (12.3) [35] | |
25.7 (16.3) [43] | 29.1 (16.5) [42] | 26.5 (15.4) [32] | 13.9 (8.0) [12] | 25.3 (14.5) [21] | 29.6 (16.4) [32] | |
SJC66, mean (SD) [N1]d | 15.5 (12.7) [49] | 12.7 (8.6) [41] | 15.6 (12.6) [34] | 11.0 (7.2) [18] | 14.6 (11.2) [28] | 16.1 (12.6) [28] |
12.4 (8.0) [50] | 13.5 (8.5) [36] | 14.8 (9.6) [33] | 10.3 (5.9) [13] | 11.4 (7.4) [16] | 14.2 (8.7) [35] | |
13.2 (10.8) [43] | 13.9 (11.0) [42] | 11.9 (10.3) [32] | 7.9 (5.1) [12] | 13.0 (8.5) [21] | 14.1 (11.6) [32] | |
PASDAS, mean (SD) [N1]d | 6.4 (1.1) [98] | 6.5 (1.1) [90] | 6.6 (1.1) [83] | 5.9 (1.3) [27] | 6.4 (1.1) [38] | 6.8 (1.1) [52] |
6.5 (1.1) [116] | 6.7 (1.1) [97] | 6.7 (1.1) [90] | 6.4 (1.0) [22] | 6.3 (1.2) [29] | 7.0 (1.1) [65] | |
6.3 (1.1) [108] | 6.4 (1.2) [89] | 6.5 (1.1) [79] | 5.8 (1.2) [24] | 6.8 (0.9) [29] | 6.7 (1.0) [58] | |
DAPSA, mean (SD) [N1]d | 54.8 (25.1) [101] | 51.5 (24.3) [93] | 52.6 (24.1) [86] | 41.9 (23.3) [27] | 49.3 (18.5) [38] | 60.1 (26.2) [54] |
56.8 (26.9) | 57.0 (26.2) | 60.5 (26.8) | 44.1 (21.2) [22] | 49.3 (25.8) [29] | 63.9 (27.5) [66] | |
50.3 (26.0) | 52.8 (25.8) | 53.1 (25.0) | 33.6 (15.6) [24] | 50.6 (21.3) [29] | 59.9 (26.5) [58] | |
CPDAI, mean (SD) [N1]e | 11.0 (2.2) [62] | 11.3 (2.2) [61] | 11.4 (2.1) [60] | 11.0 (2.1) [20] | 10.7 (1.9) [27] | 11.9 (2.2) [41] |
11.3 (2.5) [70] | 11.7 (2.2) [57] | 11.9 (2.1) [52] | 11.1 (2.5) [14] | 10.9 (2.3) [24] | 12.4 (2.2) [44] | |
10.8 (2.6) [67] | 11.1 (2.2) [61] | 11.2 (2.4) [55] | 10.3 (2.6) [18] | 12.1 (1.7) [25] | 11.5 (2.4) [41] | |
FACIT-F total score, mean (SD) [N1]d | 26.3 (11.0) [101] | 26.2 (11.0) [93] | 25.0 (12.1) [86] | 25.4 (12.3) | 25.0 (10.4) | 26.0 (11.6) [72] |
25.0 (10.5) | 24.9 (9.8) | 24.3 (9.1) | 27.2 (10.8) | 30.1 (10.6) | 23.1 (8.9) | |
27.5 (11.0) | 26.2 (10.3) | 27.6 (10.3) | 31.2 (9.5) | 26.6 (12.3) | 26.7 (9.9) | |
Arthritis pain (VAS), mean (SD) [N1]d | 58.0 (21.2) [101] | 57.6 (21.0) [93] | 60.5 (21.0) [86] | 55.1 (30.1) | 60.9 (18.0) | 58.1 (19.7) [72] |
59.3 (21.4) | 61.0 (22.1) | 59.8 (22.6) | 61.4 (22.5) | 50.6 (24.8) | 62.0 (20.6) | |
53.7 (23.8) | 57.3 (23.2) | 56.5 (22.6) | 48.2 (25.4) | 59.4 (21.4) | 55.7 (22.9) |